Tenofovir disoproxil fumarate for the treatment of HIV infection

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 3, 2006, Pages 459-469

  Pham, Paul A ^a   Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral therapy; HIV infection; Nucleotide analogue reverse transcriptase inhibitor; Tenofovir

Indexed keywords

EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ADENINE; ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33846408013     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.3.459     Document Type: Article

References (80)

1. SCHAMBELAN M, BENSON CA, CARR A et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society -USA panel. J. Acquir. Immune Defic. Syndr. (2002) 3:257-275.
2. BARBARO G: Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr. HIV Res. (2006) 4:79-85.
3. GALLANT JE: Antiretroviral drug resistance and resistance testing. Top. HIV Med. (2005) 13:138-142.
4. 4. MOORE RD, KERULY JC, GEBO KA et al.: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J. Acquir. Immune Defic. Syndr. (2005) 39:195-198.
5. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. (1999) 5:512-517. 6. Landmark paper demonstrating persistence of HIV in resting CD4 cells, suggesting that HIV infection cannot be eradicated using antiretroviral therapy.
6. BARDITCH-CROVO P, DEEKS SG, COLLIER A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45:2733-2739.
7. LOUIE M, HOGAN C, HURLEY A et al.: Determining the antiviral activity of treatment-naïve chronically HIV-1-infected individuals. AIDS (2003) 17:1151-1156.
8. WAINBERG MA, MILLER MD, QUAN Y et al.: In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. (1999) 4:87-94.
9. KEARNEY BP, FLAHERTY JF, SAYRE JR et al.: Effect of formulation and food on the pharmacokinetics of tenofovir DF (Abstract 3). 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands (2001).
10. HAWKINS T, VEIKLEY W, ST CLAIRE RL et al.: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. (2005) 39:406-411.
11. BLANCHARD JN, WOHLFEILER M, CANAS A et al.: Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin. Infect. Dis. (2003) 37:e57-e62.
12. KARRER U, LEDERGERBER B, FURRER H et al.: Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS (2005) 19:1987-1994.
13. NEGREDO E, BONJOCH A, PAREDES R, PUIG J, CLOTET B: Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin. Infect. Dis. (2005) 41:901-905.
14. + T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 19:569-575.
15. RAY AS, OLSON L, FRIDLAND A: Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. (2004) 48:1089-1095.
16. KEARNEY BP, SAYRE JR, FLAHERTY et al.: Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J. Clin. Pharmacol. (2005) 45:1360-1367.
17. MAITLAND D, MOYLE G, HAND J et al.: Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS (2005) 19:1183-1188.
18. TORTI C, QUIROS-ROLDON E, REGAZZI M et al.: Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. (2005) 10:505-513.
19. VAN LUNZEN J, SCHEWE K, KUHLMANN B et al.: High rate of virological failure during once daily therapy with tenofovir + didanosine 250 mg + efavirenz in antiretroviral-nalve patients - results of the 12-week interim analysis of the TEDDI trial [Abstract TuPp0306]. Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
20. Viread (tenofovir disoproxil fumarate) prescribing information. Gilead Sciences, Foster City, CA, USA (2005).
21. TABURET AM, PIKETTY C, CHAZALLON C et al.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
22. JOHNSON M, DEJESUS E, GRINSZTEIN B et al.: Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV-infected patients with multiple virologie failures: 96-week results from a randomized, open-label trial, BMS AI424045 [Abstract PL 14.4]. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004).
23. Reyataz (atazanavir) prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA (2006).
24. GALLANT J, PARISH M, KERULY J, MOORE R: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse transcriptase inhibitor treatment. Clin. Infect. Dis. (2005) 40:1194-1198.
25. MOLINA JM, WILKIN A, DOMINGO P et al.: Once-daily versus twice-daily lopinavir/ritonavir in aniiretroviral-naive patients: 96-week results. [Abstract WePe12.3C12]. 3rd LAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
26. GALLANT JE, STASZEWSKI S, POZNIAK AL et al.: Efficacy and safety of tenofovir DF versus stavudine when used in combination with lamivudine and efavirenz in antiretroviral naïve patients: a 3-year randomized trial. JAMA (2004) 292:191-201. Large multi-centre trial comparing tenofovir DF with stavudine in combination with lamivudine and efavirenz. The results of this trial led to inclusion of the tenofovir DF-based regimen as a preferred regimen in the DHHS guidelines.
27. GALLANT JE, DEJESUS E, ARRIBAS JR et al.: Tenofovir DF, emtricitabine and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. N. Engl J. Med. (2006) 354:251-260. Large multi-centre trial comparing tenofovir DF plus emtricitabine with lidovudine/lamivudine in combination efavirenz. This is the first clinical trial to demonstrate superiority of an antiretroviral regimen (by intention-to-treat analysis) over zidovudine/lamivudine plus efavirenz, which has been a gold-standard regimen for many years.
28. GALLANT JE, RODRIGUEZ AE, WEINBERG WG et al.: Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. (2005) 192:1921-1930.
29. KHANLOU H, YEH V, GUYER B et al.: Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS. (2005) 19:135-140.
30. DELAUNAY C, BRUN-VEZINET F, LANDMAN R et al.: Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol. (2005) 79:9572-9578.
31. JEMSEK G, HUTCHERSON P, HARPER E: Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [Abstract 51]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004). The four references above document the unanticipated failure of the triple-NRTI regimens of tenofovir DF, lamivudine, and either abacavir or didanosine. The reasons for the failure of this regimen are still unclear, but may have to do with the low genetic barrier to resistance to such combinations.
32. PODZAMCZER D, FERRER E, GATELL JM et al.: Early virological failure and occurrence of resistance in naïve patients receiving tenofovir, didanosine and efavirenz. Antivir. Ther. (2004) 9:S172.
33. KURITZKES DR: Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. J. Infect. Dis. (2005) 192:1867-1868.
34. SQUIRES K, POZNIAK AL, PIERONE G et al.: Tenofovir disoproxil fumarate in nucleoside-resistam HIV-1 infection: a randomized trial. Ann. Intern. Med. (2003) 139:313-320. The most important study leading to approval of tenofovir DF, showing improved response to addition of tenofovir DF versus placebo to a previously failing regimen.
35. MCCOLL DJ, MARGOT NA, WULFSOHN M et al.: Patterns of resistance emerging in HIV-1 from amiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J. Acquir. Immune Defic. Syndr. (2004) 37:1340-1350.
36. MARGOT NA, ZHONG L, WULFSOHN M, CHENG AK, MILLER MD: Probability and durability of achieving < 50 copies/ml of HIV RNA by treatment intensification with tenofovir DF (TDF) [Abstract H1077]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
37. MILLER MD, MARGOT N, LU B et al.: Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect. Dis. (2004) 189:837-846.
38. WHITE KL, MARGOT NA, WRIN T et al.: Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R t M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. (2002) 46:3437-3446.
39. BAE A, WALTERS J, MARGOT N et al.: Pre-existing L74V is a risk factor for virologic non-response and development of K65R in patients receiving tenofovir DF [Abstract 158]. 8th International HIV Drug Resistance Workshop. Tenerife, Canary Islands, Spain (2004).
40. SORIANO V, PUOTI M, BONACINI M et al.: Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 19:221-240.
41. DOREG J, COOPER DA, POZNIAK,AL et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. (2004) 189:1185-1192.
42. OGEDEBE AO, THOMAS DL, DIEHL AM: Hyperlactataemia syndrome associated with HPV therapy. Lancet (2003) 3:323-337.
43. BIRKUS G, HITCHCOCK MJM, CIHLAR T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside analog transcriptase inhibitors. Antimicrob. Agents Chemother. (2002) 46:716-723. In vitro study comparing relative mitochondrial toxicity of various nucleoside analogues as well as tenofovir.
44. FENG JY, MURAKAMI E, ZORCA SM et al.: Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triph osphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemotber. (2004) 48:1300-1306.
45. BIRKUS G, HAJEK M, KRAMATA P et al.: Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ, and ε. Antimicrob. Agents Chemother. (2002) 46:1610-1613.
46. BIESECKER G, KARIMI S, DESJARDINS J et al.: Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys, and woodchucs. Antiviral Res. (2003) 58:217-225.
47. RIBERA E, PARADINEIRO J, SAULEDA S et al.: Improvement of subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir [Abstract 860]. The LIPOTEST study. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005).
48. MILINKOVIC A, LOPEZ S, VIDAL S et al.: A randomized open study comparing the effect of reducing stavudine dose versus switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine [Abstract 857]. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005).
49. MOYLE G, SABIN C, CARTLEDGE J et al.: Factors associated with limb fat recovery in a prospective randomized comparative study of thymidine replacement with either tenofovir DF or abacavir in persons with clinical lipoatrophy [Abstract PE9.3/2]. With European AIDS Conference. Dublin, Ireland (2005).
50. MADRUGA JVR et al.: Impact of switching off d4T on lipids and limb fat [Abstract TuPe2.2b12]. 3rd International AIDS Society Conference. Rio de Janeiro, Brazil (2005).
51. DASILVA B, ALBRECHT M, BENSON C et al.: Improved metabolic profile with replacement of stavudine by tenofovir DF after 6 years of a lopinavir/ritonavir-based regimen. [Abstract 62]. 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland. Antivir. Ther. (2005) 10:L38.
52. PEYRIERE H, REYNES J, ROUANETI et al.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune Defic. Syndr. (2004) 35:269-273.
53. BLICK G, GRIEGER-ZANLUNGO, GARTON T, HATTON E, LOPEZ RJ: Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis. [Abstract 718]. 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2003).
54. IZZEDINE H, HULOT JS, VITTECOQ D et al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. (2005) 20:743-746.
55. KARRAS A, LAFAURIE M, FURCO A et al.: Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. (2003) 36:1070-1073.
56. RIFKIN BS, PERAZELLA MA: Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am. J. Med. (2004) 117:282-284.
57. HANSEN AB, MATHIESEN S, GERSTOFT J: Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J. Infect. Dis. (2004) 36:389-392.
58. BARRIOS A, GARCIA-BENAYAS T, GONZALES-LAHOZ J et al.: Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS (2004) 18:960-963.
59. JAMES CW, STEINHAUS MC, SZABO S et al.: Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy (2004) 24:415-418.
60. ZIMMERMANN A, PIZZOFERRATO T, BEDFORD J et al.: Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. (2006) 42:283-290.
61. GALLANT JE, PARISH MA, KERULY JC et al.: Tenofovir and changes in renal function [letter reply]. Clin. Infect. Dis. (2005) 41:571.
62. ANTONIOU T, RABOUD J, CHIRHIN S et al.: Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. (2005) 6:284-290.
63. FDA Antiviral Drug Products Advisory Committee Meeting, Tenofovir Disoproxil Fumarate. Silver Spring, Maryland, USA (2001).
64. 64. POWDERLY W, COHEN C, GALLANT JE et al.: Similar incidence of osteopenia and osteoporosis in ART-naïve patients treated with tenofovir DF or stavudine in combination with lamivudine and efavirenz over 144 weeks. [Abstract 823] 12th Conference on Retrovirus and Opportunistic Infections. Boston, USA (2005).
65. TARANTAL AF, CASTILLO A, EKERT JE, BISCHOFBERGER N, MARTIN RB: Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J. Acquir. Immune Defic. Syndr. (2002) 29:207.
66. HAZRA R, GAFNI R, MALDARELLI F et al.: Safety, tolerability, clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks [Abstract 928] 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, USA (2004).
67. GIACOMET V, MORA S, MARTELLI L et al.: A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J. Acquir. Immune Defic. Syndr. (2005) 40:448-450.
68. MATHIAS A, PLUMMER A, SKILLINGTON J et al.: Bioequivalence of efavirenz/emtricitabine/tenofovir DF single tablet formation. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006).
69. GUPTA SK, EUSTACE JA, WINSTON JA et al.: Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. (2005) 40:1559-1585.
70. TSAI C-C, FOLLIS KE, SABO A et al.: Prevention of SFV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science (1995) 270:1197-1199.
71. KEARNEY BP, LIAW S, YALE K et al.: Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment. [Abstract P4]. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2002).
72. WHITE KL, MARGOT NA, WRIN T, PETROPOULOS CH, MILLER MD, NAEGER LK: Molecular mechanisms of resistance to human immunodeficiency virus type I with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. (2002) 46:3437-3446.
73. GARCIA-LERMA G, MACINNES H, NIDTHA S et al.: In vitro selection of the T215Y and K65R mutations by stavudine and demonstration of high-level resistance to stavudine. Antiviral Ther. (2002) 7:S28.
74. MILLER MD, MARGOT NA, MCCOLL DJ, COAKLEY DF, CHENG AK: Final 144 week resistance analysis for treatment-naive patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). [Abstract 5757]. XV International AIDS Conference. Bangkok, Thailand (2005). Characterisation of resistance patterns among previously naive patients failing therapy in the 903 trial.
75. MCCOLL DJ, MARGOT NA, CHENG AK, MILLER MD: Development of K65R versus thymidine analog-association mutations (TAMs) in antiretroviral-treated patients. [Abstract P206]. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2002).
76. NAEGER LK, MARGOT NA, MILLER MD: ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type I reverse transcriptase. Antimicrob. Agents Chemother. (2002) 46:2179-2184.
77. MARGOT NA, ISAACSON E, MCGOWAN I et al.: Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J. Acquir. Immune Defic. Syndr. (2003) 33:15-21.
78. MILLER MD, MARGOT N, LU B, ZHONG L, CHEN SS, CHENG A, WULFSOHN M: Genotypic and phenotypic predictors of the magnitude of response to tenofovir DF in antiretroviral-experienced patients. J. Infect. Dis. (2002) 189:837-846. Determination of clinical cutoffs for tenofovir resistance for use in phenotypic resistance testing.
79. http://www.unaids.org AIDS Epidemic Update December (2005). UNAIDS publication CP125.
80. http://www.hivatis.org Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2006). HIV/AIDS Treatment Information Service Website. This document was updated 4 May 2006. In addition to providing treatment guidelines, it serves as a comprehensive review of the relevant literature and available data on antiretroviral therapy of HIV-infected patients.